Molecular Partners' Novel CD3 Switch-DARPin Platform To Be Highlighted At SITC 2024 With Proof-Of-Concept Data
Molecular Partners' Novel CD3 Switch-DARPin Platform To Be Highlighted At SITC 2024 With Proof-Of-Concept Data
Molecular Partners的新型CD3交换机-云计算概念板块将在SITC 2024展示，并附有概念数据。
- Preclinical proof-of-concept data supports CD3 Switch-DARPin platform for T cell engagers with enhanced function in solid tumors
- Biomarker data on completed phase 1 study of MP0317 (FAP x CD40) shows intended and marked tumor microenvironment modulation
- 在固体肿瘤中，47海丰国际桥蛋白技术平台支持CD3交换机-云计算和具有增强功能的T细胞结合物的临床前概念数据
- 已完成的MP0317（FAP x CD40）一期研究的生物标志数据显示预期和显著的肿瘤微环境调节
资讯热榜
更新时间